Episodes (Page 3)
✨
ENV-294, an oral Rac2 modulator, showed promise in a phase 1b study for atopic dermatitis.
Leon Kircik
✨
Nemolizumab sustained positive outcomes in moderate to severe atopic dermatitis for three years.
✨
Recognizing hidradenitis suppurativa in skin of color needs careful palpation and pigmentary awareness.
✨
Nemolizumab's real-world safety and tolerability in atopic dermatitis were discussed.
✨
Survodutide, a dual GLP-1/glucagon agonist, demonstrated superior weight loss versus placebo.
✨
Mavacamten received FDA approval for symptomatic obstructive hypertrophic cardiomyopathy in adolescents.
✨
Upadacitinib showed feasibility and efficacy in a trial for palmoplantar pustulosis.
✨
Denifanstat showed sustained acne control over 52 weeks in moderate to severe cases.
✨
Corticosteroids are vital in dermatology but face access challenges.
Kristina Derrick
✨
Atacicept stabilized kidney function in IgA nephropathy patients over 104 weeks.
Sayna Norouzi
✨
Ochsner Health celebrates 10,000 organ transplants across multiple organs.
✨
Ochsner's multidisciplinary approach expands liver transplant access.
Ari Cohen, MD, MBA
✨
Efsitora alfa-gobe (Onswik) approved for type 2 diabetes.
✨
Ochsner Transplant Institute reached 10,000 transplants, expanding eligibility.
✨
FDA approved a second once-weekly basal insulin, efsitora alfa-gobe (Onswik).
✨
Annual UACR screening for diabetes is recommended but underutilized.
✨
Corticosteroid Stewardship Alliance aims to influence policy and coverage.
Killian Lozach
✨
Patient advocate Briana Banos shares views on topical steroid withdrawal.
Briana Banos
✨
Mepolizumab reduced COPD exacerbations in smokers and former smokers.
✨
Diabetes Dialogue covers FDA approval of Onswik, a weekly basal insulin.